HK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet

Stock News12-04

JACOBIO-B (01167) rose over 6% intraday, with gains narrowing to 5.51% by press time at HK$8.04, recording a turnover of HK$8.15 million. The company announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital. This payment strengthens the group's cash reserves and supports further R&D of innovative oncology therapies. Additionally, JACOBIO recently revealed that clinical Phase I/IIa results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) were published in The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first global publication of systematic clinical data on dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 in the prestigious journal.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141302430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141302430","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet","media":"Stock News","content":"<p>JACOBIO-B (01167) rose over 6% intraday, with gains narrowing to 5.51% by press time at HK$8.04, recording a turnover of HK$8.15 million. The company announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital. This payment strengthens the group's cash reserves and supports further R&D of innovative oncology therapies. Additionally, JACOBIO recently revealed that clinical Phase I/IIa results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) were published in The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first global publication of systematic clinical data on dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 in the prestigious journal.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | JACOBIO-B (01167) Surges Over 6% Intraday as Subsidiary Receives RMB125M Upfront Payment and Combination Therapy Published in The Lancet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-04 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) rose over 6% intraday, with gains narrowing to 5.51% by press time at HK$8.04, recording a turnover of HK$8.15 million. The company announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital. This payment strengthens the group's cash reserves and supports further R&D of innovative oncology therapies. Additionally, JACOBIO recently revealed that clinical Phase I/IIa results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) were published in The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first global publication of systematic clinical data on dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 in the prestigious journal.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1141302430","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141302430","pubTimestamp":1764815652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) rose over 6% intraday, with gains narrowing to 5.51% by press time at HK$8.04, recording a turnover of HK$8.15 million. The company announced that its subsidiary, Beijing Jacobio,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"港股动向|雅可比-B(01167)盘中大涨超6%子公司获1.25亿元预付款联合疗法发表在《柳叶刀》","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) rose over 6% intraday, with gains narrowing to 5.51% by press time at HK$8.04, recording a turnover of HK$8.15 million. The company announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital. This payment strengthens the group's cash reserves and supports further R&D of innovative oncology therapies. Additionally, JACOBIO recently revealed that clinical Phase I/IIa results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) were published in The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first global publication of systematic clinical data on dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 in the prestigious journal.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141302430","isCrawlerRequest":true}